The University of Liverpool’s Philip Leverhulme Equine Hospital has installed a standing equine MRI scanner from Hallmarq Veterinary Imaging.
AviPro Salmonella vac E, the live oral vaccine against Salmonella enteritidis made by Lohmann Animal Health, is now available in larger size vials of 5,000 doses, supplied in packs of ten. More information from: Anna-Christina Riebau, Lohmann Animal Health, Germany. Telephone: +49 (0) 4721 747 217
Vetoquinol has launched Rimifin® a non-steroidal anti-inflammatory drug (NSAID) for dogs, containing carprofen. Carprofen can reduce inflammation and pain caused by musculo-skeletal disorders and degenerative joint disease. It can also be used as a follow-up to parenteral analgesia in the management of post-operative pain following soft tissue surgery. Rimifin® is available in a range of tablet sizes, 20mg, 50mg and 100mg. A single 100mg tablet can treat a 50kg dog.
Fort Dodge (makers of Equest equine worming brands, and Deosect), is launching a new Equine Parasites Reference Manual.
The manual, which is supported by AHDA, AMTRA and BEVA, is billed as 'an objective and comprehensive reference guide covering endoparasites and ectoparasites and their control, as well as offering prescribing tips, a glossary of terms and reference sources'.
Fort Dodge has produced the manual to provide an ‘all in one’ guide to support veterinary professionals and Suitably Qualified People (SQPs) involved in prescribing equine parasite treatments. It brings together, in an A5 spiral bound booklet, all the information they may need on the full range of licensed veterinary medicines to control equine parasites of concern in the UK. It will be launched at BETA (17-19 February at the NEC).
For further information about the manual (or to get a copy), please contact Fort Dodge on 01489 781711.
Hill's Pet Nutrition has announced that Canine i/d™ is now available again from wholesalers.
The company says that Canine i/d has been reformulated to improve texture quality, while still retaining the nutritional profile that makes i/d ideal for dogs with digestive problems and as a post-surgery recovery diet.
Hill’s Prescription Diet Canine i/d Recovery Packs are back early March; Hill's recommends use of regular i/d in the interim.
For more information, speak to your Territory Manager, or ring Hill’s Customer Services on: 0800 282438 (UK), or: 1 800 626002 (IRL)
Pfizer Animal Health has launched Dexdomitor, a new, advanced form of the popular sedative /analgesic Domitor (medetomidine).
According to Pfizer, Dexdomitor contains only the right-handed enantiomer (dexmeditomidine) which is responsible for the beneficial pharmacological effects of the meditomidine molecule. By removing the left-handed enantiomer (levomedetomidine) from the original racemic mixture the same sedative and analgesic effects can be achieved with a lower metabolic load, less potential for interaction with other drugs and half the active substance.
According to Dr Jo Murrell, Senior lecturer in veterinary anaesthesia in Bristol Vet School, the use of dexmedetomidine has a number of advantages in terms of veterinary use:
"Because dexmedetomidine had to undergo a lot of safety studies to get market authorisation in humans, we have a huge amount of cardiovascular data about the effects of dexmedetomidine in dogs,” she said. “That means we know very precisely the effects of dexmedetomidine on cardiac output, on organ blood flow and the changes in blood flow to vital organs such as the heart and brain."
Dr Murrell recommends that vets who are currently using Domitor should consider switching to Dexdomitor when it becomes available.
"You won’t notice any disadvantages as a result of the switch, but you may well notice that the effects of dexmedetomidine are more reliable compared to medetomidine, and you may notice some benefits in terms of recovery from anaesthetic combinations."
Bayer Animal Health has doubled the number of pipettes in its Advocate all-in-one flea, worm and mite spot-on to provide an additional range of six-month treatment packs for cats and dogs.
Bayer says the doubling of the number of pipettes in a pack is aimed at providing vets with greater prescribing flexibility and to help improve compliance for owners over a six-month period. Bi-annual vet visits will now give a full year’s parasite cover with Advocate.
Advocate is now available in three- and six-pipette packs for small and large cats and for medium, large and extra large dogs, and three-pipette packs for small dogs. The product remains the only combined flea, worm and mite spot-on that is licensed for the treatment of A. vasorum in dogs.
Researchers at the University of Edinburgh’s Royal (Dick) School of Veterinary Studies are to start testing whether a compound of cooling chemicals, extracted from mint, can be used to treat laminitis, a condition which affects seven per cent of the British horse population.
The new project, funded by The Horse Trust and led by Professor Sue Fleetwood-Walker, builds on recent work that revealed for the first time that, there is significant nerve damage, as well as inflammation, within the hoof of laminitic horses. This explains why anti-inflammatory drugs are so ineffective in treating the pain of chronic laminitis and highlights the need for therapies to treat nerve injury-induced or ‘neuropathic’ pain in horses.
Prof Fleetwood-Walker’s team discovered in 2006 that the ‘mint’ chemicals have a pain–killing effect in laboratory studies of chronic pain. They will now investigate whether this synthetic treatment could help horses with laminitis.
Alstoe Animal Health has launched Dolagis, a carprofen tablet for dogs that uses a unique delivery system which the company claims offers palatability and dosage benefits over other versions of this analgesic.
Called Delicament, the delivery system is essentially a clever tablet design which allows a single table to break easily and accurately into four pieces. That allows correct dosing for all dogs above 3kg, from just one tablet size. Delicament has also been designed to be highly palatable, both in terms of flavour (pig's liver, before you ask) and texture.
To further simplify practice stocking requirements, Dolagis comes in only one pack size, complete with dispensing envelopes that explain how to split the tablet.
Dolagis 50mg tablets are packed in individually perforated blister strips of 10 tablets to aid prescribing accuracy and product integrity. This also reduces the chance that high palatability can lead to patient self-consumption. There are 100 tablets per Dolagis pack, which are available from all wholesalers. For further information contact Alstoe on 01347 878606 or email info@alstoe.co.uk.
Two recently published studies have demonstrated that the canine anti-emetic Cerenia® (maropitant - Pfizer) which was launched last year also relieves car sickness in dogs.
In a pilot study, 17 dogs were given either Cerenia or placebo one hour before being taken on a car journey. After a washout period of 10-14 days, each dog was crossed over to the other treatment and once again taken on a journey to assess travel sickness. The results showed that likelihood of vomiting was reduced by 70% when the dogs were given Cerenia compared to placebo – but due to the small number of dogs enrolled the results did not reach statistical significance.
The same research group also carried out a large, multicentre, blinded and placebo controlled study of Cerenia in preventing vomiting in 213 dogs known to be prone to travel sickness. They were given a single oral dose of Cerenia or placebo one hour before a car journey. The results showed that Cerenia was associated with a reduction in vomiting of 79% compared to placebo (p<0.0001).
The dosage of Cerenia used in both studies was 8mg/kg dose for the prevention of motion sickness–higher than the 2mg/kg dose that is routinely used to treat general emesis, administered at least one hour before the journey. According to the researchers’ report in the Veterinary Record, the need for a higher dose is linked to the specific neural (central) pathway of emetic stimulation that is involved in motion sickness. Cerenia acts primarily at NK1 receptors in the emetic centre and thus has the ability to block vomiting due to vestibular stimuli.
According to Pfizer, a single oral dose lasts for at least 12 hours, so pets can be dosed the night before an early start. For motion sickness prevention, Cerenia is licensed for up to 2 days’ consecutive use, so owners can use it for a return journey the next day if need be.
Pfizer also says that market research suggests almost one in five dogs suffers from travel sickness, which is not only inconvenient but does also stop some owners from travelling with their pet. In the past, owners have had to rely on OTC (over the counter) remedies or medicines developed for use in humans to prevent travel sickness. Many of these are ineffective or have unwanted effects such as sedation or extrapyramidial effects in dogs. Cerenia is the first anti-emetic to be developed specifically for use in dogs and was launched in April 2007– higher dose tablets aimed specifically for the prevention of travel sickness are expected to be made available early this year.
Genitrix has launched a scheme to help vet practices generate revenue through increasing sales of its canine mobility product, C2Collaplex. The scheme offers a money-back guarantee if clients and practices don’t see clear benefits from using C2Collaplex on dogs with mobility problems within a month.
In order to validate the scheme, clients are asked to complete a simple mobility score sheet and return it to the practice one month from the date of their original consultation. If both vet and client agree that C2Collaplex has made no difference, the practice will refund the client and Genitrix will forward on a replacement pack of C2Collaplex.
C2Collaplex, designed to promote the continuation of normal joint function in ageing and less mobile dogs, contains a range of nutritional substances, including Glucosamine HCl, Chronodroitin Sulphate, Vitamin C and Manganese, which help to support the musculo-skeletal system.
In addition, it contains purified Type II collagen which is the major protein of the cartilage in the joints. C2Collaplex is the only veterinary product to provide this protein in a purified form. According to Genitrix, it works by helping to switch off adverse processes and keeps cartilage normal.
In a retrospective study of 100 dogs presenting to practice with mobility problems, C2Collaplex was given as the only supportive agent and over 80% of veterinary surgeons and owners perceived a benefit from its use.
Commenting on the launch of ‘C2Collaplex Money Back Guarantee Scheme,’ Rob Watkins, Marketing Director of Genitrix, said: “The C2Collaplex Money Back Guarantee Scheme offers a win/win. It gives pet owners a well-priced, next generation product, which will help their dog. For the practice, it helps to build a strong revenue stream, with the guarantee of a refund if it fails to help an individual patient.”
For further information on participating, practices should contact Genitrix on 01403 786345.
In response to growing demand for graduates equipped for a wide range of careers in veterinary and biomedical science, the Royal Veterinary College (RVC) has developed the BSc (Hons) course in Bioveterinary Sciences.
The Bioveterinary Science degree supersedes the BSc Veterinary Sciences that has been offered by RVC since 2002. Graduates go on to pursue careers within the biotechnology and pharmaceutical industries, veterinary-related professions, and biomedical research.
Prospective students interested in finding out more about the course are invited to attend an open day on Wednesday March 12 at the Camden Campus in London. Members of staff will be on hand to discuss aspects of the BSc in Bioveterinary Sciences degree, including entrance requirements and teaching and research facilities. In addition, current students will lead a tour of the London campus and talk about student life at the College. Further information and an online booking form can be found at http://www.rvc.ac.uk/
VetCell is celebrating a win at Cheltenham, after 'Knowhere' won the Cotswold Chase following pioneering stem cell treatment for a serious tendon injury.
Knowhere had had a good start to his racing career as a four-year-old, winning his first two races as a novice hurdler. But after his second race in 2004 he suffered injuries to both forelimb superficial digital flexor tendons. The left fore showed low grade tendonitis while the right fore had a significant percentage of fibre rupture. As a promising racing prospect, Knowhere’s connections wanted to give him the best possible chance of recovering from his injury so they opted for stem cell therapy. He was treated by Tim Beauregard MRCVS of Summerhill Farm in Gloucestershire.
Bone marrow samples were collected from Knowhere’s sternum and were processed in VetCell's laboratory over a five week period to generate millions of stem cells. Knowhere was sedated, the tendon area was anaesthetised and the leg was then surgically clipped and disinfected. Stem cells, which had been suspended in serum obtained from the original bone marrow sample, were then injected using ultrasound guidance, into the core of the damaged area of the tendon fibres.
For the first week after the implantation Knowhere was kept in his stable to allow the cells to adapt to their new environment. Each day after this he was given walking exercise in order to stimulate the activity of the stem cells, encouraging them to differentiate into tendon cells and form into strong tendon fibres. The amount of exercise was incrementally increased, building up over a three-month period from five minutes each day to 45 minutes twice a day.
By the autumn of 2005 both of Knowhere’s tendons had healed very well and showed good fibre pattern on ultrasonography. He was re-introduced to the racetrack the following year and of the 15 or so races he has been in since, he has finished in the frame on eight occasions and has amassed some £175,000 in winnings.
Vet Tim Beauregard said: “Knowhere’s successful return to the track has been exciting and immensely satisfying to follow and he showed particularly brilliant form in the Cotswold Chase. It remains to be seen whether he will be heading for the Ryanair Chase, the Gold Cup or the Grand National but all involved will be hoping for the best.”
For more information please contact VetCell on +44 207 691 2062 or 866 764 0340, email: info@vetcell.com or visit the website at http://www.vetcell.com/
Animus4Vets has launched a new complete series of training CDs. The new series of 4 CDs is entitled Sales and Merchandising and covers aspects such as consulting room sales, waiting room sales and educational displays.
Animus4Vets says the new CDs have been designed in a similar format as their first Client Care series and aim to enable veterinary practices to run their own in-house training.
For more information go to http://www.animus4vets.com/ and follow the CD training links or phone 01449 775330.
Prac-tic® – the spot-on flea and tick treatment from Novartis Animal Health has added a new claim to its licence.
It now states that adult fleas are killed before they lay eggs for a minimum of four weeks after treatment and, as the product completely eliminates egg production, it also breaks the flea life cycle.
Hot on the heels of the new license claim for Prac-tic comes the news that Novartis has launched new tasty Milbemax for cats.
The new tablet is the same small size as the original, but is beef-flavoured to ensure high palatability. According to Novartis, trials show that 100 per cent of cats accept the treatment with wet food and 83 per cent with dry food.
To help promote worming the palatable way, Novartis is offering practices some tasty marketing tools to use including posters, client leaflets, worming reminder pads and even a sturdy cut-out cat for reception.
Novartis will also be running a ‘Name Our Cat’ competition with the chance to win an iPod touch complete with an educational podcast; there are five to be won. Entry details can be obtained from Novartis Territory Managers.
For more information about new tasty Milbemax, please contact your Novartis Animal Health Territory Manager or call the Practice Support Line on 0800 854100.